Point of care tests for hospital-acquired infections (HAIs) : economic analysis report by Szczepura, Ala & Osipenko, Leeza
 
 
 
 
 
 
 
 
Detection & Identification of Infectious Agents (DIIA) 
Innovation Platform: Health Econometrics 
 
ECONOMIC ANALYSIS REPORT 
Point of Care Tests for Hospital-Acquired Infections 
(HAIs) 
 
 
Prepared by Division of Health Sciences, Warwick Medical School  
for  
UK Technology Strategy Board 
 
 
June 2009 
 
 
 
 
 
 
Research Team: 
Professor Ala Szczepura, Warwick Medical School 
Dr Leeza Osipenko, Senior Scientific Adviser, Scientific Advice Team, NICE & 
Honorary Fellow Warwick Medical School 
 
Contact: 
Ala Szczepura, Professor of Health Services Research, 
Warwick Medical School, University of Warwick, Coventry CV4 7AL 
ala.szczepura@warwick.ac.uk 
 
 
Detection & Identification of Infectious Agents (DIIA) Innovation Platform 
Area B: Hospital Acquired Infections (HAIs) 30 June 2009 1 
 
Detection & Identification of Infectious Agents (DIIA) Innovation 
Platform: Health Econometrics 
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1. BACKGROUND 
 
A number of clinical/disease areas have been prioritised by the Technology Strategy Board (TSB) 
and Department of Health (DH) for the DIIA Innovation Platform.  To support commissioning of 
technology development for detection of hospital acquired infections (HAIs) in humans, a scoping 
review has been undertaken to help identify the specific requirements for new diagnostic test 
development and likely economic payback for point of care (POC) tests for HAIs in the UK. 
 
This report presents economic analysis findings for the following HAIs: 
 
 Methicillin-resistant Staphylococcus aureus (MRSA) 
 Clostridium difficile (C. difficile) 
 Extended-spectrum beta-lactamase (ESBL) infections. 
 
 
2. FRAMEWORK 
 
An evaluative framework was developed within which any new POC diagnostic technology could 
be considered.  The final framework was agreed with the TSB and Department of Health.  The 
study adopted a pre-defined methodology.  The health economics team undertook literature 
reviews, evidence synthesis, and economic modelling/early-health technology assessment 
(HTA) of POC tests for each infection type.  Independently, a scientific team examined the 
characteristics of existing laboratory tests for these infections and outlined the performance 
parameters required for an ‘ideal’ POC test.  These ideal test parameters were then used in 
economic modelling, along with evidence from the literature review. 
 
The health economic scoping study was based on two main elements: (i) UK burden of 
illness: estimation of national costs associated with each infection (including mortality, 
morbidity and treatment costs) and the cost of diagnosis and screening using current tests; 
(ii) UK economic model: POC testing scenarios were mapped against existing tests to 
estimate any clinical or cost consequences (on positives detected, false negatives/false 
positives reported, infections transmitted, and healthcare and mortality costs) and the likely 
impact of widespread POC test introduction was estimated.  The main analysis focused on 
estimating incremental direct costs on moving from current tests to a new POC test.  For 
different scenarios, the model estimated the total cost of resource use and the number of 
infections detected.  Historical costs extracted from the literature were inflated to 2007/08 
prices.  A one-day workshop was held in which preliminary findings from the model were 
presented to national experts.  The model was then further refined based on expert opinion 
and additional information provided by group members.  The model excluded longer term 
impact on antibiotic resistance which is difficult to quantify robustly in monetary terms. 
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3. ECONOMICS 
 
3.1  Hospital-acquired infections (HAIs) 
 
There has been considerable growth in literature on the economics of various hospital-acquired 
infections (HAIs) in recent years.  This is thought to be due both to a need to understand the 
financial implications of HAIs, and because of pressure to demonstrate the cost-effectiveness of 
infection control systems.[1]  At the same time, it is acknowledged that there is a need to develop 
more sophisticated policy models for estimating the economic impact of HAIs and evaluating the 
cost-effectiveness of interventions designed to reduce these[2]. 
 
The present report focuses on infections acquired in hospitals.  Assessment of the economics of 
infections acquired in other institutions such as care homes is outside the remit of the present report; 
this represents an important gap in any discussion of new point of care (POC) tests.  The care 
home sector (residential and nursing homes) is an important provider of care for older people.  
There are currently 441,000 beds for adults in 19,000 care homes in England; this compares with 
167,000 beds in the hospital sector.[3]  Annual expenditure by local authorities on personal care 
services for care home residents is currently estimated at £4.8 billion (2004/5) with spend predicted 
to rise more rapidly than on home care.[4]  The Department of Health is currently updating its 
guidance on infection control in care homes; a final version is not yet available.
1
  
 
3.1.1 HAIs: Economic burden of disease 
 
In the USA HAIs represent the fifth leading cause of deaths in hospital, and the financial burden is 
estimated at $6.5 billion ($7.08 billion, 2007 prices) per annum.[2]  In the UK, HAIs have been 
reported to be a contributory factor in more than 5,000 deaths per year [5], with an estimated 
300,000 cases in 2001.[6]  An in-depth UK study identified a 13% death rate for inpatients with an 
HAI; compared to 2% for those without.  Even after adjusting for patient demographics, clinical 
condition etc, individuals who acquired an infection were reported to be 7.1 times more likely to 
die.[7] 
 
Nationally, it has been estimated that HAIs add £986.4 million (£1.3 billion, 2007 prices) to NHS 
costs.[7]  The most recent NAO report similarly quotes an annual cost for all HAIs in excess of £1 
billion [5]; this figure is not expected to change in the revised version
2
  Post-discharge costs 
represent a small proportion of this total figure; downstream costs for outpatient visits total £26.8 
million, GP follow up £8.4 million, and district nurse visits £20.5 million.  The majority of the 
impact on hospital cost (£507.77 million, 55%) is associated with multiple infections.  For single 
infections, UTIs represent the largest economic burden for the hospital system (£160 million in 
total, 2007 prices), the burden from surgical site infections (SSIs) is lower (£81million, 2007 
prices), and blood stream infections on their own represent additional costs of £33 million (2007 
prices).[7]  These figures exclude compensation paid out by the NHS to victims of MRSA and C. 
difficile.  This was reported to be almost £7.5 million in 2007/08, with a further £42 million NHS 
Litigation fund for cases still pending. 
 
Because many of the costs quoted above are based on 1995 data, even after inflation to current 
prices they probably underestimate the current cost of HAIs following the rise in MRSA and C. 
difficile cases since 1995.  A recent US analysis has identified overall annual direct hospital medical 
costs of between $28.4 and $45 billion per annum (2007 prices) for all HAIs.  After adjusting for 
                                            
1
 Personal communication, Dr C Bowman, Medical Director BUPA Care Homes. 
2 Personal communication, NAO. 
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the range of effectiveness of possible infection control interventions, the benefits of prevention are 
estimated to range from a low of $5.7 to $6.8 billion (20 percent of infections preventable) to a high 
of $25.0 to $31.5 billion (70 percent of infections preventable).[8] 
 
3.1.2 HAIs: Cost of current treatment and control 
 
Approximately one in ten of all patients in an NHS acute hospital will acquire an HAI.[9]  Post 
discharge, it has been reported that a further 19% who were negative in hospital will report an 
infection.[7]  
 
A recent review of economic analyses of general HAIs has identified that the quality of papers is 
generally poor.[2]  Numerous studies indicate that HAIs are associated with increased length of 
hospital stay, and also worse outcomes for patients.[7, 10-15]  In general, the highest incremental 
cost per patient is reported for bloodstream infections or bacteraemia.[10, 11]  Standardising 
published results, a mean extra cost per patient of $36,441 (£19,199, 2007 prices) is estimated for 
blood stream infections.[2]  Surgical site infections (mean $25,546; £13,459, 2007 prices) and 
ventilator assisted pneumonia (mean $9,969, £5,252 2007 prices) have the next highest incremental 
cost.  A single UTI in general adds least to the cost of a hospital stay (mean $1,006; £530, 2007 
prices). 
 
In the UK, an average cost of £4,400 (2007 prices) per patient is reported for general HAIs; this 
figure includes staff, treatment and overhead costs.[7]  Analysis by infection site indicates that 
general blood stream infections add the most at £7,600 per case; respiratory infections add £3,400; 
and surgical wound infections £2,300.  Multiple site infections add the greatest cost to a hospital 
stay (£13,000, 2007 prices). 
 
Only one UK study provides information on costs incurred after discharge.[6, 7]  These are £58 per 
patient for infections diagnosed prior to discharge, and £23 for infections only reported post-
discharge.  Personal costs, time off work and informal carer costs add a further £832 for infections 
diagnosed before discharge, and £441 for those occurring post-discharge. 
 
 
3.2  MRSA: Economic disease burden & testing and treatment costs 
 
Summary figures for the calculations below are presented in Table 2. 
 
3.2.1 MRSA: Economic burden of disease 
 
In the UK, MRSA is among the HAIs of highest economic concern.[16]  The proportion S. aureus 
isolates that are methicillin resistant is ≥ 25% [17].  In other countries, levels are lower (<3%) in 
Scandinavia, Switzerland and the Netherlands; similar (> 30%) in Spain, France, Italy and Portugal; 
and much higher in the USA (64%) and Japan (74%).[9] 
 
The economic burden associated with MRSA is likely to decrease in the UK.  Figures for 
bacteraemia (~25-30% overall mortality [18, 19]) have shown a significant fall from 6,383 cases in 
2006/07 to 4,450 in 2007/08 following government initiatives.[20]  With the introduction of MRSA 
screening for all hospital admissions by 2011, this trend is likely to continue.  Therefore, although 
we present current data below, we suspect that figures may need to be adjusted down to 
accommodate declining rates of hospital acquired MRSA. 
 
MRSA mortality: 
The number of deaths mentioning MRSA in England and Wales increased from 51 to 1,652 
between 1993 and 2006.[21]  In 2007, 460 death certificates in England and Wales reported that 
MRSA was the underlying cause of death, and a further 1,133 mentioned it as a contributory cause.  
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However, a confidential report found considerable under-reporting of MRSA on death certificates 
(~35% reported).[22]  This would indicate a ‘true’ figure of 1,314 deaths, rather than 460. 
 
The age profile for MRSA deaths in 2007 shows 1,104 (69%) in the 85 and over age group, 429 
(27%) in the 45-85 group, and 60 (4%) in the under 45 age group.[21]  Applying this age profile, 
together with the average UK life expectancy of 79.4 years [23], to the 460 MRSA deaths in 2007 
we estimate ~2,560 Life Years (LYs) lost.  This equals a mortality cost of ~£69 million per annum 
in England and Wales (assuming health related quality of life (HRQoL) of 0.7; life year valued at 
£38.8k, discount rate not applied).  For a ‘true’ figure of 1,314 deaths, the mortality cost would 
rise to ~£198 million p.a. as shown in Table 2. 
 
MRSA morbidity: 
It is not possible to estimate the UK morbidity burden associated with hospital acquired MRSA.  
The annual number of infections required to calculate this cannot be identified accurately.  Only 
bacteraemia figures are routinely reported, but MRSA wound infections are known to be four times 
higher than bacteraemia [24], with MRSA now accounting for 24% of all surgical site 
infections.[25]  Totalling wound infection and bacteraemia numbers indicates at least 22,250 
MRSA infections in England in 2007/08; this excludes infections detected in other samples such as 
urines and catheters. 
 
An alternative way of estimating an upper MRSA figure is to start with the 15.7 annual hospital 
admissions in England.  Based on a reported 7% prevalence rate [9, 26-29], it can be estimated that 
~1 million patients will enter hospital each year colonised with MRSA.  Studies suggest that 20-
60% of these admissions will go on to develop an MRSA infection.[30, 31]  Taking the lower figure 
of 20% would suggest a total of ~200,000 MRSA hospital infections annually in England if these 
patients are not decolonised. 
 
Even if this figure could be estimated accurately, it is not possible to estimate the number of 
QALYs lost and therefore a morbidity cost since the impact on HRQoL for individuals following an 
MRSA infection has not been reported in any studies. 
 
MRSA costs to society: 
In the UK, a loss of between £3 billion and £11 billion annually to the economy has been reported 
due to MRSA, to include a real fall in gross domestic product through lost work/output.[32]  
Another study estimates that between £300 million and £1,750 million worth of UK healthcare and 
social services are lost each year due to MRSA.[33]  In the USA, the cost has been estimated at 
between $US17 billion and $US30 billion, discounting the costs of litigation.[34] 
 
3.2.2 MRSA: Cost of current treatment and control 
 
For the calculations below, Annex 1a provides an overview of input parameters and assumptions 
used to estimate costs. 
 
MRSA inpatient care: 
Estimating the extra cost associated with hospital acquired MRSA is difficult because attributing 
an incremental cost to these HAIs will be confounded by case-mix and severity of the patient’s 
underlying condition.[34, 35]  Not all published studies control for these factors.  The global cost to 
the NHS due to MRSA infections has been reported as more than £45 million per annum.[36]  
There is agreement that the main cost driver is the impact on hospital length of stay.[37, 38]  
Isolation policies can also increase costs significantly with an isolation cost (over and above 
standard bed day costs) of about £50 per patient/day.[15, 39, 40]  Contact precautions (antiseptic 
hand washing, wearing a plastic apron and gloves) are less expensive; estimated at ~£13.5-£14.5 per 
patient/day in the UK.[9]  A course of vancomycin is approximately £530. 
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In the UK, an average increase in inpatient cost has been estimated as £4,798 (2007 prices) per 
MRSA case.[7]  This is lower than studies reported in other countries; for example, in Canada, 
$CAN14,360 (£7,800, 2007 prices) [12]; in the USA, $US9,794 (£7,800) for bacteraemia [13] 
and $US13,901 (£12,000, 2007 prices) for post-surgical wound infections [14]; in France, 
$US9,275 (£7,400, 2007 prices) for ICU cases [15]; and in Israel for ICU patients, US$33,889 
(£17,000, 2007 prices)[19].  Lower incremental costs are also reported for a teaching hospital in 
Spain, €2,730 (£2,100, 2007 prices).[41] 
 
Using the UK figure of £4,798 per MRSA infection (2007/08 prices), combined with a figure of 
~22,250 cases, the annual impact on inpatient care costs is estimated at ~£106.75 million in 
England (see Table 2).  This excludes ad hoc government initiatives such as the £50 million scheme 
to "deep clean" every hospital in England.  It also excludes the cost to the NHS of general infection 
control in hospitals, since this is difficult to apportion to particular HAIs. 
 
MRSA decolonisation: 
For NHS patients who are colonised with MRSA, decolonisation (comprising antibacterial 
shampoo and body wash and the application of an antibacterial nasal cream) is relatively 
inexpensive at £7.60 per patient (2008/09 prices).  Since Trusts should now be screening all elective 
admissions [42], annual decolonisation costs are estimated at ~£6.9 million (allowing for false 
positives).  By 2011, once emergency admissions are included, an additional cost of £2.5 million 
will be incurred for decolonisation. 
 
3.2.3 MRSA: Cost of current testing 
 
MRSA unit test costs: 
Published unit test costs for individual tests specified in Section 2.1 are shown in Table 3.  These 
figures only include consumable costs and should therefore be treated with considerable caution.  
One UK study has estimated full test costs, which include sampling, staff time, lab overheads etc. in 
addition to consumable costs.[9]  For solid media (agar) the full unit cost is calculated to be £7.80 
(for a positive test) and £5.06 (negative); and for broth enrichment it is £10.16 (positive) and £6.97 
(negative).  For real-time PCR (SmartCycler system with IDI MRSA Test Kit) the cost per sample was 
estimated to be ~£26.46 (negative and positive). 
 
MRSA diagnostic testing costs: 
In cases in where an infection is suspected, a diagnostic test will be requested.  Assuming that one 
sample is tested from each patient and that ~20% of these are positive (see above), the cost per 
patient tested is estimated at ~£5.61 for agar and ~£7.61 for broth enrichment.  Nationally, based on 
>22,250 MRSA infections (>111,250 patients tested if 20% of samples are positive), and the 
assumptions above, the cost of diagnostic testing is estimated as ~£0.2 – £0.3 million per annum 
in England. 
 
MRSA screening programmes: 
The NHS is committed to introducing MRSA screening for all elective admissions from 2008/09; 
and to extending this to cover all emergency admissions by no later than 2011.[43]  The cost of 
screening will be significantly higher that the diagnostic test costs calculated above.  The 
Department of Health has estimated that, in England, the cost of screening plus decolonisation over 
10 years will total £1.22 billion.[42]  Although several studies report that the benefits of MRSA 
screening are not yet proven [44-47], other papers suggest that implementing screening in 
conjunction with contact precautions can result in a significant reduction in MRSA cases.[48, 49] 
 
For current screening tests, based on a single swab per patient and an assumed 7% prevalence rate 
[9, 26-29], use of a standard agar plating pre-admission test for 95% of electives and rapid PCR for 
the remainder (see cost figures above), an annual screening cost of £68.4 million is estimated for 
electives, as shown in Table 2.  In 2011, once emergency admissions are included, assuming that 
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rapid PCR tests are used for all of these and standard agar for the rest, this figure will increase to 
£181.88 million. 
 
For current screening (electives only), if all swabs are tested using PCR the annual screening cost 
rises to £290.4 million; if all were to be tested using standard agar it would fall to £57.8 million. 
 
 
3.3  C. difficile: Economic disease burden & testing and treatment costs 
 
Summary figures for the calculations below are presented in Table 2. 
 
3.3.1 C. difficile: Economic burden of disease 
 
Clostridium difficile infection (CDI) remains the main cause of hospital-acquired infectious 
diarrhoea, usually beginning following antibiotic exposure.[50-52]  In terms of economic burden, 
CDI can impact on HRQoL and even be life-threatening, especially in elderly patients.[25]  As well 
as exposure to antibiotics, other risk factors include a recent stay in a long-term care facility (e.g. 
nursing home) or hospital.  After rising steadily, the number of CDI cases in patients aged 65 years 
and over decreased by 9% in 2007.  This decrease should be interpreted with caution since it may 
not be sustained. [53] 
 
C. difficile mortality: 
In 2007, 4,056 death certificates in England and Wales reported CDI as the underlying cause of 
death and a further 4,268 mentioned it as a contributory cause.[21].  Once again, there appears to be 
considerable under-reporting with ~65% of deaths where CDI was a direct or probably cause not 
reported as such on death certificates.[22]  This indicates that the ‘true’ number of deaths in 2007 
with CDI as the underlying cause might be ~11,590.  Considering all cases where CDI might have 
contributed to death, and allowing for under-reporting, this figure may actually be as high as 
~23,780 deaths.  Since only 22% of samples in 2007 were submitted from outside acute Trusts, it is 
likely that the majority of CDI deaths are linked to hospital infections. 
 
The median age at death is not reported, although 82% of cases occur in the 65+ age group.[25]  
Comparative rates show ~3,400 deaths per million population in the 85+ age group, compared to 
~0.7 deaths per million population in the under 45 age group in 2007.[21]  Assuming a conservative 
3 years lost per death, based on average UK life expectancy figures [23], we estimate ~12,168 Life 
Years (LYs) lost linked to the 4,056 deaths in England and Wales specifying CDI in 2007.  This 
represents a total mortality cost of ~£330 million (assuming HRQoL of 0.7, life year valued as 
£38.8k).  If this figure is adjusted for likely under-reporting, we estimate a total mortality cost of 
~£944 million as shown in Table 2. 
 
C. difficile morbidity: 
The morbidity burden is linked to the total number of CDI cases.  This was difficult to estimate 
while mandatory surveillance only covered cases in those aged 65 and over.  In April 2007, this was 
extended to the 2-64 years age group, enabling the total number of infections to be estimated.  In 
2007/08, there were a total of 54,746 CDI cases reported for all ages in the UK.  Just under half of 
these (24,168 cases, ~44%) were identified as hospital-acquired (detected 2+ days after admission); 
in a further 25% of cases (13,687) information was not available, giving a possible 37,850 cases of 
CDI.  Only 22% of overall CDI cases originate from outside acute Trusts, which would suggest a 
maximum possible number of ~42,700 hospital cases in 2007/08. 
 
It is not possible to estimate the number of QALYs lost through CDI due to lack of data on HRQoL.  
However, complications such as multiple CDI recurrences, intestinal perforation, sepsis and 
colectomy will clearly have a long-term impact on quality of life.[54]  Also, new CDI strains are 
linked to increased disease severity, with 10% of these patients requiring colectomies, which will 
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impact on quality of life.  Any trend of decreasing age for patients with CDI will also increase the 
QALY burden since any impact on HRQoL could extend over a greater number of years. 
 
C. difficile costs to society: 
No published UK studies provide an estimate of societal costs such as lost productivity/missed days 
of work resulting from CDI.  The cost of CDI has been estimated as €3 billion/ year in the EU, 
equivalent to £400 million in a population the size of the UK; this figure appears low and may not 
include societal costs. [50]  A similarly broad range has been reported by researchers in the USA, 
from $436 million to more than $3 billion societal costs. [55-57] 
 
3.3.2 C. difficile : Cost of current treatment and control 
 
For the calculations below, Annex 1b provides an overview of input parameters and assumptions 
used to estimate costs. 
 
C. difficile inpatient care: 
In the case of CDI, there is once again agreement that the main cost driver is the impact on hospital 
length of stay for the index episode, plus subsequent re-admissions to hospital.[58]  Two UK 
studies have measured the incremental cost of CDI for hospital cases.  A UK retrospective study 
calculated an average value of £3,000 per case at 2007/8 prices, with 93.8% of the additional cost 
linked to increased LOS. [59]  A UK prospective study in a geriatric ward found a total cost 
difference of £4,107 (£5,600 at 2007 prices); 94% of the cost was due to increased LOS. [60] 
 
Internationally, other studies have reported a difference of £6,750 (2007 prices) [61]; an increase in 
total hospital cost of $15,180 [62]; and a difference of €4,067-9,276. [63]  A US study reports the 
largest incremental cost ($US22,600) for CDI in patients undergoing a major bowel procedure.[64]  
A large US 5 year retrospective analysis has shown that CDI is an independent predictor of 
increased LOS, total charges and mortality rates after surgery; total charges were found to increase 
by US$77,483 per patient.[65]  For ICU patients, another study has reported a difference in cost of 
$US6,510.[66] 
 
Assuming a conservative incremental cost of ~£4,300 in the UK (based on the £3,000 and £5,600 
figures reported in the two UK studies above), CDI in 2007/08 is estimated to have increased 
inpatient care costs by £183.6 million for the index episode for ~42,700 hospital cases. 
 
Re-admissions to hospital: 
It is reported that approximately 20% - 27% of patients will have at least one CDI recurrence, with 
some patients experiencing as many as 14 episodes; recurrence rates for older patients (≥65 years) 
are reported to be particularly high, reaching 59.4% [67-69].  The additional cost associated with an 
index CDI episode will therefore not be limited to the inpatient stay in which infection occurred. 
 
A retrospective analysis of hospital stay for patients admitted to hospital with recurrent CDI 
demonstrated a lifetime cost per patient approximately 3.5 times that of the initial episode.[70]  A 
study in 19 Canadian hospitals estimates a similar cost increase for patients with re-admissions 
(average of 10 re-admissions).[71]  These studies exclude the cost of complications, additional 
clinic visits, community care, and time lost from work, so the full healthcare cost increase is under 
estimated, as are associated societal costs. 
 
Assuming that 20% of CDI cases in the UK (lower figure above) lead to recurrent episodes, and that 
the lifetime cost of care for such cases is 3.5 times higher, the estimated total national longer-term 
cost associated with CDI cases in 2007 will rise by 50% to £202 million per annum for 42,700 
cases, to include subsequent re-admissions. 
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3.3.3 C. difficile : Cost of current testing  
 
Our literature search was unable to identify any robust costing studies for the specific CDI tests 
mentioned in Section 2.1 (shown in Table 3).  Absence of unit test cost figures which include 
staffing, capital and overheads is a major gap in the evidence base. 
 
One UK study reported that the additional testing cost per CDI case was approximately £210 (£290 
at 2007 prices).  However, intensity of daily testing was largely similar for CDI and non-CDI cases, 
so that the cost difference was mainly linked to an increased LOS (equal to an average ~£9.85 per 
day). [60] 
 
Assuming that 10% of hospital samples are positive for C. difficile toxins [72], 427,000 patients will 
be tested to identify ~42,700 cases.  This equates to a total testing cost of £4.3 million at a unit test 
cost of £10.  In the community setting, only 2% of samples are positive. 
 
 
3.4  ESBL: Economic disease burden & testing and treatment costs 
 
Summary figures for the calculations below are presented in Table 2. 
 
3.4.1 ESBL: Economic burden of disease 
 
A number of key risk factors for acquiring ESBLs have been identified as listed in Section 1 of the 
report.  From an economic point of view, it is important that ESBL-producing bacteria are 
associated with increased morbidity as well as mortality [73]; and that patients with this infection 
require longer hospital stays than patients who are not infected with ESBL-producing strains.[74]  
Recent articles on paediatric ICUs, reporting similar ESBL prevalence to that observed in adults, are 
also important in terms of the potential length of impact on HRQoL.[75-80]  
 
Although recent detection of ESBL producing E. coli associated with UTIs in the community 
are economically important [81-83], they are outside the remit of the current economic 
assessment.  This trend may have important cost consequences if it leads to an increased need for 
parenteral antibiotics to treat UTI in the community. [82, 84] 
 
ESBL mortality: 
In the UK, the number of deaths each year in patients with infections caused by ESBL-producing 
bacteria is not known.  It is therefore not possible to accurately estimate ESBL mortality costs 
for the UK. 
 
Assuming that mortality is principally linked to blood stream infections, with a total of ~5,500 cases 
of ESBL E. coli bacteraemia in 2007 reported in the UK (excluding Scotland), and assuming a 
conservative mortality rate of ~5% - 10%, this would indicate ~275-550 deaths per annum 
(excluding Scotland) for E. coli infections.  However, even this is likely to be a gross underestimate.  
Firstly, since it is based on voluntary reporting only.[74]  Secondly, much higher mortality rates 
have been reported for patients with ESBL CTX-M with ESBL contributing directly to mortality in 
19% of cases, and a contributing factor in a further 7.5%.[85]  As a consequence, the number of 
ESBL-related deaths may be much higher. 
 
Since an age profile for deaths involving ESBL-producers is not available, it is not possible to 
accurately estimate the number of Life Years lost or the associated mortality cost for ~275-550 
deaths.  Paediatric deaths will have greater economic consequences in terms of Life Years lost and 
associated mortality costs.[86]  Assuming an average 10 years of life lost per person, this 
represents a total mortality cost of ~£74.69 - £149.4 million (assuming HRQoL of 0.7, life year 
valued as £38.8k) as shown in Table 2. 
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Finally, it is worth noting that it is still not universally accepted that ESBL infection is 
responsible for increased mortality.[87]  Although a number of studies do report mortality rates, 
these vary in terms of whether they report crude mortality or mortality attributable to ESBL, and 
whether they include all ESBL-positive strains or focus on more virulent pathogens; they also 
almost exclusively focus on patients with bacteraemia.  A recent meta-analysis examined reported 
impact on mortality for bacteraemia caused by Enterobacteriaceae.[88]  The authors report a crude 
mortality of 20% among non-ESBL patients and 34% as the expected mortality among ESBL 
bacteraemia.  However, these bacteraemia findings contrast with those from 8 other studies that 
included patients with other types of ESBL infection, where increased mortality was found in only one 
study.  For intensive care units, a recent qualitative review of the literature concludes that ESBL-
producing Enterobacteriaceae are generally associated with increased mortality in univariate 
analyses, although associations sometimes disappeared in multivariate analyses.[89] 
 
However, there is consistent evidence that the main reason for mortality among patients with ESBL 
bacteraemia is a delay in initiating effective treatment.[90-92]  A case-control study of inpatients 
with E. coli, Klebsiellia or Proteus bacteraemia found that patients with ESBL-positive strains 
were more likely to have a delay of > 48 hours to appropriate antibiotic therapy (66% versus 
7%; P< 0.001).[93]  In another prospective study of patients with K. pneumoniae at 12 
hospitals in seven countries, failure to administer an appropriate antibiotic within the first 5 
days resulted in significantly higher mortality than treatment with an appropriate antibiotic (63.6% 
versus 14.1%; P= 0.001).[94] 
 
ESBL morbidity: 
It is not possible to accurately estimate the morbidity burden associated with ESBL infection in UK 
hospitals.  Comprehensive data on the annual number of infections are limited.  For bacteraemia, 
the HPA has estimated ~2,000 infections due to ESBL E. coli in the UK (excluding Scotland).[95]  
Summing 2007 data for ESBL bacteraemia due to E. coli, Klebsiella and Enterobacter produces a 
figure of ~5,500 bloodstream infections.[85, 96]  This data is based on voluntary reporting; it also 
excludes other infection sites (e.g. UTIs), so is likely to significantly underestimate the annual total 
number of ESBL-linked infections.  Another source suggests a total of ~30,000 infections due to 
ESBL-producing E. coli alone each year in the UK.[95]  Although the majority of ESBL cases are 
associated with UTIs, a significant minority of patients do have bacteraemia (40% in a review in the 
South East).[96] 
 
Even if an accurate figure could be obtained for the annual number of ESBL infections, the QALY 
loss could not be estimated since the HRQoL of patients with ESBL infections has not been 
reported.  The new severe strains (e.g. CTX-M) may have a greater impact on HRQoL.  A number 
of studies report that delays in administering appropriate antibiotics contribute to increased 
morbidity, as well as mortality.[90-94].  Thus, there appears to be good evidence that the ESBL 
morbidity burden could be reduced through more rapid identification, but no quantitative data to 
allow this to be estimated. 
 
ESBL costs to society: 
There is no literature reporting the annual loss to the UK economy from ESBL infections. 
 
3.4.2 ESBL: Cost of current treatment and control 
 
Annex 1c provides an overview of input parameters and assumptions used to estimate costs below. 
 
ESBL inpatient care: 
As with other HAIs, the impact on hospital length of stay is reported to be the most important cost 
driver.  However, to date the impact of ESBL infection on inpatient costs has been assessed in 
only a small number of studies.[97]  Once again, separating the additional cost to the NHS from 
the underlying cost is difficult.  
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In the USA, patients with ESBL-producing E. coli or K. pneumoniae are reported to incur 
significantly greater hospital charges than matched controls (difference $44,359 per 
patient).[98]  Even after controlling for APACHE II score and LOS before infection, infection 
with an ESBL-producing strain still nearly doubles charges.  A more recent matched-cohort 
study of patients infected with ESBL-producing E. coli or Klebsiella at sites other than the 
urinary tract reported a difference of $16,451 per patient.[99]  A third study of patients with E. 
coli, Klebsiellia spp. or Proteus spp has reported that ESBL-positive cases had a significantly 
higher average hospital cost (difference $30,093 per patient) .[93]  After adjusting for 
various potential confounding variables, ESBL still remained independently associated with 
increased hospital costs (P= 0.003). 
 
Because there is no published UK economic study, we have assumed an incremental 
inpatient cost based on the lowest figure above ($16,451 or £8,225).  Combining this with 
the estimated ~30,000 infections due to ESBL-producing E. coli alone, produces a conservative 
annual increase in inpatient care costs of £246.75 million 
 
3.4.3 ESBL: Cost of current testing  
 
Our search of the literature was unable to identify any robust published costing studies for the 
ESBL tests listed in Section 2.1 (and associated Table).  This, together with the lack of data on 
numbers diagnosed and the prevalence of ESBL in samples tested, means that the national cost of 
ESBL testing cannot currently be estimated. 
 
 
3.5  MRSA: Cost-effectiveness of individual tests & current testing 
 
3.5.1 MRSA: Evidence on cost-effectiveness of testing 
 
Our review of the literature identified relatively few studies reporting the cost-effectiveness of 
individual tests for diagnosing MRSA.  Most recent papers focus on economic evaluation of 
screening for various types of hospital admission. 
 
MRSA diagnostic testing: 
For diagnostic samples, overall test effectiveness will depend not only on rapid antibiotic treatment 
for the patient diagnosed with MRSA infection, but also on introduction of control measures to limit 
transmission to other patients such as use of isolation rooms or cohorting.  Expert opinion suggests 
that lapses in hand hygiene and aseptic practice would not, typically, represent more than 10% of 
cases.[42] 
 
Section 2.1 (and associated Table) in the scientific report indicates that available MRSA tests are 
reported to have a range of sensitivity and specificity values.  There is uncertainty over reported 
accuracy since papers do not generally meet accepted quality criteria, not least because there is no 
agreed reference standard for MRSA testing.[9]  For modelling screening in Scotland, agar culture 
has been assumed to have a sensitivity of 68% (6% incidence of false-positives); broth enrichment 
culture a sensitivity of 98% (6% false-positives); and real-time PCR a sensitivity of 92% (9% false-
positives).[9]  An impact assessment by the Department of Health assumed tests had 90% 
sensitivity and 95% specificity.[42]  If a test has a low sensitivity, risk to other patients will be 
increased as false negative MRSA patients may be managed in the open ward.  If the test specificity 
is low (higher false positives) beds in isolation facilities may be occupied unnecessarily. 
 
Table 3a demonstrates the broad range of costs reported for tests listed in Section 2.1.  However, 
since there is no reliable data to confirm which tests are most widely used in the UK (i.e. market 
share) it is difficult to draw conclusions about overall cost-effectiveness in the NHS.  Furthermore, 
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there is uncertainty over the effectiveness of control measures which may be used following a 
positive test result, especially the independent effects of one measure in comparison with 
another.[100] 
 
MRSA Screening programmes: 
There is more evidence on the cost-effectiveness of MRSA screening tests.  Tests will inevitably 
misclassify some patients as screen positive or negative in the same way as screening tests for other 
infectious disease.[101]  The effectiveness of any screening programme will also depend on the 
efficacy of decolonisation and any associated interventions (e.g. isolation/cohorting) as well as the 
risk for a particular patient group.  The impact of MRSA infection can be particularly serious in 
certain specialties.[102]  Infections may still occur in patients who are known to be colonised with 
MRSA and for whom decolonisation treatment is ineffective.  Decolonisation is reported to be only 
50-60% effective for long-term clearance [103]. 
 
A number of recent articles (2006-08) provide mixed evidence on the economics of MRSA 
screening, with findings generally presented in the form of a ‘cost analysis’.  Cost-utility analyses 
(i.e. cost/ QALY) are absent.  Several studies report that screening is cost-effective, although the 
cost-effectiveness of rapid PCR testing is questioned in three studies. 
 
 A study in a teaching hospital in Spain has estimated that the cost of a programme would be 
covered if it prevents 4 infections per year (11% of total infections).[41]  A similar study in 
Germany has estimated that €20,000 could be saved by detecting and successfully 
decolonising a total of five patients through pre-admission screening in general 
surgery.[104]  
 
 In the USA, the cost-effectiveness of screening all patients admitted to medical and surgical 
and intensive care units for MRSA nasal carriage has been assessed over a 15 month period.  
The authors report an estimated $US19,714 saving per month through averted MRSA 
infections.[105]  Rapid pre-admission testing for US patients undergoing elective surgery is 
predicted to produce a mean annual hospital cost saving of $US231,538,400 in another 
study.[106]  Rapid PCR testing of hospital readmissions among previous MRSA carriers is 
reported to reduce isolation days by 54% and reduce costs from $US113.2 to 
$US62.1.[107] 
 
 In Switzerland, a cohort study has evaluated rapid molecular MRSA screening in ICU.  This 
was observed to substantially reduced MRSA cross-infections in the medical but not in the 
surgical ICU.[108]  Another Swiss study reports that use of PCR for contact screening for 
MRSA carriage increased costs by 104,328 Swiss francs (CHF) but only saved CHF 38,528 
for pre-emptive isolation. It is concluded that, in patient populations with low endemic 
MRSA, the use of PCR is probably not cost-effective.[109] 
 
 In Germany, a hospital-wide screening programme was judged to prevent 48% of 
predicted hospital-acquired MRSA infections resulting in a net annual saving of 
€110,237.[40]  
 
 In France, a cluster randomised trial has examined whether rapid testing reduces MRSA 
acquisition.  No evidence was found of a significant reduction in MRSA acquisition and it 
was concluded that it is unlikely that the increased costs of rapid tests can be justified, 
compared with alternative control measures against MRSA.[47] 
 
 A Canadian decision analysis compared the costs of detection by PCR and by culture.  Cost 
per patient was higher for detection by PCR ($CAN96) than by culture ($CAN67).  Overall 
costs increased from $CAN605,034 to $CAN771,609, with 37% of the increase due to 
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patients being placed under contact precautions unnecessarily due to low specificity of the 
PCR test.[110] 
 
 Three other studies have concluded that the clinical benefits of screening are not proven, 
although economic analyses are not included.[44-46] 
 
In the UK, it is estimated that although screening would cost the NHS £1.22 billion over 10 years in 
England, it would actually result in cash saving in treatment costs of MRSA bacteraemia and wound 
infections of £1.19 billion.[42]  This calculation assumes that all elective admissions will receive a 
pre-admission test (standard agar), and that emergencies will be screened using a rapid PCR test.  
Economic modelling in Scotland suggests that real-time PCR is unlikely to replace culture for 
blanket MRSA screening of patients, primarily because test accuracy is lower than for enrichment 
broth.[9]  This view is not supported by other authors who suggest that there may be a role for 
PCR on specific wards, where the risk of colonisation or infection is high and preadmission 
screening is not possible.[111]  The economic viability of screening will depends primarily on the 
relationship between colonisation and infection risk.  Decolonisation costs are relatively small, 
whilst benefits (including lives saved) will depend on the likelihood of a serious MRSA infection 
resulting from a colonised patient.  In the UK, it has been estimated that if risk falls to around 1 case 
per 700 colonised patients, the economic calculation becomes neutral.[42] 
 
 
3.6  C. difficile: Cost-effectiveness of individual tests & current testing 
 
3.6.1 C. difficile: Evidence on cost-effectiveness of testing 
 
There is very little published on the cost-effectiveness of existing tests for CDI.  Considering the 
high costs associated with CDI morbidity and death, this represents a major research gap.  The most 
cost-effective approach to identification will be determined by the clinical context, any recognisable 
causes, and the cost and yield of available diagnostic tests. 
 
If a test has a low sensitivity (producing false negatives), patients will not receive appropriate 
treatment.  This will lead to more serious illness for patients themselves and increased risk to other 
patients since the infected patients will not be isolated and instead managed in the open ward.  Each 
resulting transmission could lead to ~£4,300 in additional healthcare costs; more with high risk patients 
e.g. in ITU.  If test specificity is low (producing false positives) antibiotic treatment for other 
conditions may be stopped and patients treated inappropriately for CDI.  Beds in high cost isolation 
facilities may also be occupied unnecessarily and if the patient is nursed with other true CDI cases, 
there will be a risk of infection.  Once the infection is diagnosed, testing costs (£210) represent 
only a small fraction of overall inpatient CDI care costs.[60] 
 
CDI diagnostic testing: 
As speed of diagnosis is important for the efficient use of isolation facilities, clinicians need to 
ensure that faecal specimens are sent for testing as soon as infective diarrhoea is suspected.[22]  
Tests detecting toxins are considered to be more cost-effective.[112] 
 
There are now more than a dozen commercial antibody-based tests
 
for C. difficile on the market.  
Although these tests may be perceived as cost-effective, any incorrect results will add to the cost of 
care (see above).  A meta-analysis reporting on 6 toxin detection kits found that PPV is generally 
poor (less than 50% in some cases).[113]  The fact that many laboratories have introduced these kits 
is likely to have increased the number of incorrect results. 
 
The use of these kits to diagnose C. difficile has been questioned recently, especially in the context 
of widespread testing.[114]  However, an economic analysis of the cost-effectiveness of toxin 
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detection kits has not been undertaken in the NHS.  If the first test from a patient is negative, 
experts recommend that a second test be performed to definitely rule-out disease. 
 
CDI screening strategies: 
Because most samples tested for CDI are negative (90% of hospital samples and 98% of 
community ones [72]), an efficient, rapid screening test could not only reduce turn-around time 
for reporting negative results but also decrease overall costs.  A number of authors provide 
assessments of different screening strategies.[115, 116]  These include a two-step algorithm with a 
first stage (antigen test) followed by a culture cytotoxin assay for positive specimens [117, 118]; or 
a rapid screen by an immunoassay followed by toxin testing for screen-positive specimens, and 
stool culture for toxin-negative specimens. [119]  Such approaches are reported to offer laboratories
 
a simpler, faster, and more cost-effective testing protocol for
 
C. difficile, as well as reducing 
workload.  Although step-testing is reported to be cost-effective, the authors present no figures to 
support this statement. 
 
 
3.7  ESBL: Cost-effectiveness of individual tests & current testing 
 
The rising importance of ESBL-producing organisms necessitates effective screening methods for 
their detection.  A testing strategy for ESBL will include an initial screen using an indicator drug 
e.g. cephalosporin to identify likely producers, followed by a confirmatory test for screen-positive 
isolates.[120]  Different tests are available to help confirm ESBL susceptibility, including 
combination disc methods or the more expensive Etest ESBL strips. [121]  Alternatively, a single-
test can be used (e.g. Vitek test).  A recent review of articles (1966-May 2007) evaluating 
laboratory methods
 
for detection of ESBLs (and AmpC beta-lactamases) identified numerous 
laboratory techniques available for
 
detection of ESBLs.[122]  However, the authors conclude that 
tests currently recommended
 
can be associated with both false
 
negative and false positive results.  In 
particular, routine microbiologic testing
 
may not detect ESBLs because in vitro susceptibility does
 
not always correlate with clinical outcomes.  This may influence the utilisation of test results by 
clinicians. 
 
3.7.1 ESBL: Evidence on cost-effectiveness of testing 
 
Our review of the literature has identified very few studies reporting the cost-effectiveness of tests 
for diagnosing ESBL.  Several papers indicate that strategies currently used for patients with ESBL 
bacteraemia are inefficient and need to be revised.  A three pronged approach has been suggested to 
include facilitating diagnosis and reporting of ESBL production, revising empirical therapy choices, 
and improving definitive treatment.[93]  
 
The few studies which allegedly describe the economic impact of new detection methods for ESBLs 
are simplistic and usually do not go further than stating that a method is simple, rapid and low-
cost.[123]  One recent study concentrated on how test information is used and found that the 
majority of clinicians acted on a positive laboratory result; with 40% changing to appropriate 
monotherapy and another 23% substituting for an inactive antibiotic.[124]  A second study 
investigated clinician response to ESBL confirmation reports for E. coli or Klebsiella species
 
non-
urinary infection generated by an
 
automated detection system (MicroScan Walkaway); acceptance 
was observed in 69.2 % of the post-automated
 
detection cohort versus 20 % in the pre-automated 
detection
 
period (P 0.001).[125]  Although there was earlier
 
initiation of appropriate therapy, 
reductions in length
 
of stay and mortality were not observed. 
 
Another paper on detection of Klebsiella pneumoniae-produced ESBL in a hospital with high 
prevalence reports that the E-test demonstrated higher accuracy but was more expensive than the 
disk diffusion method.[126]  An economic review has been undertaken of this paper [127]  Total 
costs for each diagnostic strategy were estimated for different ESBL prevalence.  For the E-test, at 
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ESBL prevalence of 2% the total cost is $37,260, and at 10%, the cost is $48,332.  For the disk 
diffusion method, the cost is $44,484 at 2% prevalence, and $55,556 at 10% prevalence.  The lower 
prevalence figure may be more appropriate for the NHS.  Screening of diarrhoea samples in one UK 
hospital has shown faecal carriage of ESBL-positive E. coli in 4.6% of acute hospital in-patients. 
[96]  
 
 
3.8  Estimating the economic benefits which new tests could provide 
 
3.8.1 Overview of economic analysis and model used 
 
Current testing scenarios (Tables 4a-c): 
Tables 4a - 4c present an overview of the UK status quo for MRSA, CDI and ESBL testing 
respectively.  Comparative data are provided for the technical performance (sensitivity/specificity) 
of tests currently used; times to result; and the location of testing.  The numbers of inpatients being 
tested annually is also presented (where this can be estimated).  For MRSA (Table 4a) tests where 
an infection is suspected are distinguished from population screening tests.  For ESBL, the annual 
number of tests could not be estimated with any accuracy. 
 
The final two columns in Tables 4a-c summarise the economic impact of each infection in UK 
hospitals, as detailed in sections 3.2 - 3.4 above.  Annex 1 provides an overview of input parameters 
and assumptions used to estimate these costs. 
 
In Table 4a, the annual burden of disease for MRSA hospital infections includes costs associated 
with mortality together with incremental inpatient costs.  Morbidity costs are excluded 
(unavailable).  NHS costs incurred after discharge (GP consultations and community nurse visits) 
are also excluded; as are societal costs such as lost productivity/missed days of work. 
 
The penultimate column provides an estimate of current national expenditure on MRSA testing.  
For MRSA screening tests, two extreme testing scenarios are presented – one in which PCR tests 
only are used (maximum cost) and one using culture tests only (minimum cost).  NHS policy 
guidance does not specify which tests should be used for screening. 
 
Table 4b presents similar economic information in the final two columns for C. difficile hospital 
infections.  These indicate that CDI is associated with a higher economic burden than MRSA.  In 
contrast, annual testing costs are higher for MRSA because of the significant volume of screening 
tests.  For CDI, total testing costs are much smaller (~£4.3 million).   
 
It was not possible to estimate the current market for ESBL tests. 
 
Tables 4c provides estimates of the burden of disease for ESBL infections (although figures are 
highly speculative) 
 
New testing scenarios (Tables 5a-c): 
Tables 5a - 5c present the characteristics of an ‘ideal’ new test for detecting these 3 infections.  The 
Tables include information on test requirements (sensitivity/ specificity, time to result, and test 
process/setting) for the new test. 
 
An economic model has been constructed to estimate the predicted economic benefits at national 
level of moving from the current status quo to implementation of one of the new tests. 
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The economic model: 
A relatively simple economic model was constructed in Excel to estimate the costs of diagnosis and 
treatment (including isolation/ cohorting) of the three infections (MRSA, C. difficile and ESBL), 
and longer terms consequences such as mortality.  These were compared for different tests (status 
quo and new) 
 
In our analysis we focused on estimating incremental direct cost on moving from current testing to the 
proposed new test at year 1.  Based on different parameter assumptions, the model then estimated 
the total cost and the number of infections detected.  In the time available it was not possible to 
develop a more sophisticated model (e.g. simulation) which would be able to show national level 
costs and benefits over an extended time period. 
 
Data in the model: 
The model parameters were based on the highest level of evidence available from our review of the 
literature, and through contacting experts. 
 
The main economic drivers for the new diagnostic tests were assumed to be changes in the number 
of false negatives/false positives and increases in the number of true positives detected.  These in 
their turn were assumed to impact on the number of infections transmitted and on mortality. 
 
The impact on morbidity could not quantified due to lack of robust data (e.g. QALYs), and was not 
included in the model for any of the 3 infections. 
 
For MRSA, the reduced turn-around time for a diagnostic result (from 48 hrs for culture to 20 min 
for new Point of Care (PoC) test) was included in the model.  It was assumed that transmission of 
infection would fall to ~zero with the new PoC test.  The model was run for varying numbers of 
annual diagnostic tests (111,250 – 500,000) and for different infection transmission rates (0.3 – 0.7). 
 
In the case of CDI diagnosis, the difference turn-around time was much smaller (3 hrs for ELISA to 
20 min for new PoC).  This, combined with a lack of robust transmission rate data, meant that we 
made no attempt to estimate the impact of reduced turn-around-time in this case.  The model was 
run for an assumed 427,000 annual diagnostic tests, and for varying infection transmission rates (0.3 
– 0.7). 
 
For diagnosis of ESBL, most data items were missing.  It was not possible to estimate values for 
the main parameters required to model economic benefits.  Therefore, no attempt was made to 
quantify the economic benefits of a new PoC test (see Table 5c).  This would require a separate 
data collection exercise. 
 
For MRSA screening tests, the model computed additional true positive cases detected (see Table 
6a (ii)).  However, the monetary value placed on these could not be estimated.  This will be 
dependent on factors for which definitive data was not available; these include the likelihood of an 
individual moving from a colonised to infected state if colonisation undetected, the rate of 
colonisation transmission to other patients during the hospital stay, and the effectiveness of 
decolonisation treatment.  In our simple model, there was therefore no attempt to go beyond 
quantifying the extra colonised cases detected.  The model was run for 15.7 million screening tests 
(all electives and emergency admission), and for different infection transmission rates (0.3 – 0.7). 
 
Costs: 
For each testing scenario, we estimated the number of cases of detected/ undetected and 
treated/ untreated infections and subsequent direct cost consequences.  Indirect and intangible 
costs associated with these infections, including lost time from work, pain, anxiety, and long-
term morbidity were not included in the analysis.  Thus, the results presented below are likely 
to be an underestimate. 
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Results for MRSA: 
 
Table 6a (i) shows that changing to a new test with improved sensitivity but decreased specificity 
(Table 4a status quo versus new test Table 5a) does not necessarily guarantee national savings 
when screening and diagnostic tests are considered together.  Savings will be dependent on which 
tests are currently used for screening, the number of suspected cases tested (diagnostic tests), and 
the assumed infection transmission rate.  The Table shows that, when the new test is compared to 
culture screening in a sensitivity analysis, an annual cost saving of £1.8 to £150 million (depending 
on infection transmission rate) is predicted if the new test unit cost is similar to culture tests, and 
assuming ~111,000 tests per annum for suspected infection (diagnostic).  In this scenario, increased 
costs due to treatment of more cases will be compensated for by fewer infections transmitted (and a 
decrease in associated mortality and inpatient stay costs).  If the number of diagnostic tests rises to 
half a million, the savings increase significantly.  Under a scenario in which the unit test cost is 
similar to PCR tests, although more cases will be detected, there will be no national cost saving at 
lower diagnostic test numbers, and for higher numbers the Table shows savings will only occur at 
the higher transmission rate. 
 
Table 6a (ii) indicates that if the new test were to replace diagnostic MRSA culture tests, 
significant cost savings can also be achieved, especially if transmission rates are high (see Figure 
1a). 
 
For screening, Table 6a (iii) shows the numbers of true and false positives, plus the number of false 
negatives, if different tests are used for screening.  The estimated number of extra patients colonised 
due to the 48 hours turn-around time when culture is used as an admission screen is also included.  
The annual cost of decolonisation is presented for all 3 scenarios. 
 
Results for CDI:  
 
The costs and financial benefits of the two scenarios (Table 4b status quo versus new test Table 
5b) were similarly modelled.  Here the new test will result in improved sensitivity (more cases 
detected, model not actual) and a more rapid test result.  Two levels of improvement in test 
parameters were modelled, based on Elisa vs Assay sensitivity/ specificity values and Elisa vs 
Culture values.  In both cases, the additional cases detected will lead to extra treatment costs (which 
are relatively low), but will result in fewer infections transmitted and lower inpatient and mortality 
costs (which are relatively high).  Table 6b shows that for 427,000 patients tested per annum there 
will be an annual cost saving at higher transmission rates, but not at the lowest transmission rate 
(see also Figure 1b). 
 
For CDI, an estimate of the break-even cost for the new test can also be estimated at £49 - £173 (see 
Table 5b).  These figures are based on the sum of current total spend on testing plus the predicted 
savings resulting from improved performance of the new test, divided by the number of tests to be 
performed.  Two sets of figures are provided based on ELISA versus Culture sensitivity/specificity 
values, and on ELISA versus Assay data. 
 
A similar break-even cost figure could not be estimated for MRSA because of the number of 
scenarios considered and the associated range of parameters. 
 
Results for ESBL: 
 
Costs could not be modeled for ESBL due to a lack of robust data on key parameters. 
 
Extra cases detected: 
For each testing scenario and type of infection, we estimated the number of additional cases 
which would be detected following introduction of the new PoC test.  Table 5a shows the 
Detection & Identification of Infectious Agents (DIIA) Innovation Platform 
Area B: Hospital Acquired Infections (HAIs) 30 June 2009 17 
extra number of MRSA cases (excludes colonisations) and Table 5b the extra number of 
CDIs.  Figures could not be estimated for ESBL (Table 5c). 
 
3.8.2 Economic conclusions 
 
For MRSA diagnosis, Table 6a (ii) shows that a new PoC test could be highly money-saving.  
Table 6a (i) indicates that overall savings for diagnosis and screening will be dependent on the unit 
test cost of the new PoC test (for both minimum and maximum number of diagnostic tests 
performed).  If the PoC test can only be offered at current PCR prices, then overall the new test will 
only be money saving the higher number of diagnostic tests is performed, and transmission rates are 
high. 
 
Assuming a unit test cost equal to current culture tests, at the lower diagnostic testing level (111,250 
per annum) Table 6a (i) shows that the annual financial benefit predicted with the new test is a 
saving of £1.8 - £149.8 million.  At higher diagnostic testing levels (500,000) this figure rises to a 
maximum of £914.0 million (depending on the assumed transmission rate). 
 
Table 6a (ii) also shows that under all scenarios, moving to the new test would detect additional 
MRSA infections; 5,118 annually for the lower diagnostic testing level and 23,000 for the higher. 
 
For diagnosis of CDI, Table 6b illustrates that a new PoC test can also be money-saving, but only 
at higher transmission rates (≥0.33).  The Table demonstrates that moving to the new test would 
once again detect additional cases; 7,686 if the PoC test replaces culture and 4,270 if replacing 
Assay. 
 
All the economic benefits above have been modelled based primarily on change in test sensitivity 
and specificity.  The fact that the new test offers a shorter turn-around time has also been included 
for MRSA testing. 
 
In conclusion, due to the limited time available for this complex modelling exercise, the findings 
should be treated with some caution.  It has not been possible to develop a simulation model 
which would demonstrate economic benefits at a national level over time following 
implementation of the new PoC tests.  We recommend that this be considered for both MRSA and 
C. difficile.  In the event that more detailed specifications for the two new tests can be provided 
(what equipment will be needed, the type (and cost) of test kits, the level of staff required to 
perform the tests, whether a human reader is required etc.), it should be possible to better indicate 
relative savings linked to the new tests. 
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TABLE 2:  HAIs Economic Impact in the UK (2007) 
 
 
 
MRSA C Diff ESBL 
UK DISEASE BURDEN 
 
   
MORBIDITY 
 
   
Annual number of cases >22,250
2 
 
42,700 
 
~30,000
8
 
Morbidity: Annual QALYs lost 
 
N/A N/A N/A 
MORTALITY 
 
   
Annual number of deaths
1
 460
3 
[1,314] 
4,056
3 
[11,590] 
~275-550 
Av. age at death 
 
~85 yrs ~76 N/A 
Life Years (LYs) lost 2,560
3 
[7,313] 
12,168 
[34,770] 
N/A 
Monetary value of LYs lost ~£69 m
3 
[~£198 m] 
~£330 m
3
 
[~£944] 
~£74.7-£149.4m
9
 
UK SOCIETAL COSTS 
 
   
Annual total cost to economy 
 
£3-11 billion
4
 £400 million N/A 
NHS CARE/TREATMENT COSTS 
 
   
Annual drug therapy costs 
 
£6.9 m
5
 Included below Included below 
Annual hospital care costs 
 
>£106.75 m £202 m ~£246.8
8
 
Total annual treatment cost 
 
>£113.65 m £202 m
7
 ~£246.8
8
 
INCREMENTAL HOSPITAL 
COST/CASE 
 
   
Added cost/case  £4,798
6
 ~£4,300 
[£6,450]
 7
 
~£8,225 
 
1 
 England & Wales, 2007 figures 
2 
 England, 2007/08 estimated total figure for bacteraemia & wound infections. 
3 Deaths where infection is underlying cause [bracket: adjusted for under-reporting] 
4
 Includes productivity loss/sick benefit 
5
 Includes current decolonisation costs (based on all elective admissions screened) 
6 
 2007/08 prices 
7
 Higher figure includes estimated cost of CDI recurrence in 20%. 
8 
Figure based on ESBL-producing E. coli cases only. 
9
  Assumes an average 10 years of life lost per person. 
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TABLE 3:  HAIs Unit Test Costs (Converted to 2007 prices) 
 
Test name 
 
Cost/test (£) 
(consumables 
only) 
 
 
Source(s) 
MRSA tests   
BBL™ CHROMagar™ MRSA 
2.3 
0.86 
[129] 
[130] 
Brilliance™ MRSA Agar 0.55 www.supplychain.nhs.uk 
ChromID 0.55 www.supplychain.nhs.uk 
Staphychrom II N/A  
MRSA ID 0.76 [130] 
Mannitol salt agar with oxacillin 
(OMSA) 
N/A  
MRSA Select(R)  
0.47 
0.63 
www.supplychain.nhs.uk 
[130] 
ORSAB Select Medium N/A  
MANNITOL SALT BROTH 1.19 www.supplychain.nhs.uk 
PBP2′ latex agglutination test 
11.6$kit http://www.fishersci.com/wps/portal/ 
PRODUCTDETAIL?href=&aid=112906 
Screen Latex Agglutination Test N/A No published source 
Staphaurex® Plus 6.63$ [131] 
GeneOhm StaphSR 15.7 www.supplychain.nhs.uk 
BD GeneOhm™ MRSA Assay 14.5 www.supplychain.nhs.uk 
GenoQuick MRSA 10.39 www.supplychain.nhs.uk 
GenoType MRSA 23.52 [130] 
LightCycler N/A No published source 
ReaX PCR 25.50$  
VirEp N/A No published source 
Evigene Kit N/A No published source 
Xpert™ MRSA 26.40 www.supplychain.nhs.uk 
Velox N/A No published source 
BacLite Rapid MRSA No longer used  
CAMBR Biosensor N/A No published source 
C. difficile tests   
BBL Media N/A No published source 
Brazier CCEY Agar - Cycloserine-
cefoxitin-egg yolk agar 
N/A No published source 
C. difficile Agar Base and Supplement N/A No published source 
Clostridium difficile agar N/A No published source 
Cycloserine-cefoxitin-fructose agar N/A No published source 
BD ColorPAC Toxin A test N/A No published source 
Premier Immunocard C difficile N/A No published source 
Remel Xpect N/A No published source 
Tox A/B Quik Chek N/A No published source 
Triage C diff panel N/A No published source 
C difficile Toxin A+B N/A No published source 
C. DIFF CHEK™-30 N/A No published source 
GA Clostridium difficile Antigen N/A No published source 
Premier Toxin A+B N/A No published source 
Remel ProSpecT N/A No published source 
Ridascreen toxin A/B N/A No published source 
Toxin A/B II N/A No published source 
Vidas C. difficile Toxin A &B N/A No published source 
C. DIFF QUIK CHEK™, N/A No published source 
CDT N/A No published source 
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Test name 
 
Cost/test (£) 
(consumables 
only) 
 
 
Source(s) 
 
ESBL tests 
  
PHOENIX N/A No published source 
VITEK N/A No published source 
Cica B test N/A No published source 
MicroScan ESBL plus panel N/A No published source 
chromID ESBL N/A No published source 
Chromagar CTX N/A No published source 
Chromagar ECC N/A No published source 
BLSE agar N/A No published source 
E-test (Ceftazidime +/- clavulanic acid) N/A No published source 
E-test (Cefotaxime +/- clavulanic acid) N/A No published source 
Antibiotic discs (Cloxacillin and boric 
acid) 
N/A No published source 
Antibiotic discs 
(Cefpodoxime/clavulante) 
N/A No published source 
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TABLE 4a:  Overview and summary of current testing for MRSA (2009 scenario) 
 
Clinical 
context 
for 
diagnosis 
Current UK test 
context 
Current tests used Current test capability Current economic impact 
Number of 
UK 
patients 
tested 
annually 
Settings 
where tests 
undertaken 
Type of 
tests used 
Test 
process 
Type of 
specimen 
Time to 
perform 
test/result 
Sensitivity/ 
Specificity 
Annual 
Testing Cost
2
 
 
Annual  
Burden of 
disease  
MRSA 
screening 
 
~11 million
1
 Laboratory 
Culture 
detection 
using 
Chromagar 
Culture, 
followed by 
confirmatory 
tests 
Nasal, 
groin, 
axilla, 
wounds, 
urine 
48h 
Mean: 
Sens 72% 
Spec 97% £57.8 – 
£290.4 million 
[£68.4 million
4
]  
Mortality:  
£198 million
3
 
 
IP cost 
(incremental): 
£106.75 million 
 
Decolonisation: 
£6.9 million 
 
 
~11 million
1
 Laboratory 
Molecular 
methods 
(BD PCR) 
One step 
molecular 
tests 
Nasal 
samples 
2h 
Sens 91% 
Spec 96% 
MRSA 
clinical 
diagnosis 
111,250 - 
500,000 
Laboratory 
Culture 
detection 
Culture 
followed by 
confirmatory 
tests 
Wound, 
Blood 
48h 
Mean: 
Sens 72% 
Spec 97% 
£0.2 - £0.3 
million 
        
Total: ~£69
4 
million 
Total: £311.65 
million 
        GRAND TOTAL = ~£381 million 
1 Assumes only elective admissions are screening at present. 
2
 MRSA screening: higher figure assumes PCR is only test used; lower figure assumes only culture is used. 
   MRSA clinical diagnostic: higher figure assumes 500,000 patients tested for suspected MRSA, lower figure assumes 111,250. 
3
 Includes allowance for under-reporting of deaths. 
4
 Assuming screening uses standard agar plating pre-admission test for 95% of electives and rapid PCR for the remainder.
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TABLE 4b:  Overview and summary of current testing for C. difficile 
 
Clinical 
context 
for 
diagnosis 
Current UK test 
context 
Current tests used Current test capability Current economic impact 
Number of 
UK 
patients 
tested 
annually 
Settings 
where tests 
undertaken 
Type of 
tests used 
Test 
process 
Type of 
specimen 
Time to 
perform 
test/result 
Sensitivity/ 
Specificity 
Annual 
Testing Cost 
 
Annual  
Burden of disease  
C difficile 
clinical 
diagnosis 
427,000 Laboratory ELISA One step test Faeces 3h 
Mean†: 
Sens vs 
Culture 77% 
Spec vs 
Culture 95% 
Sens vs 
Assay 85% 
Spec vs 
Assay 95% 
£4.3 million 
Mortality: £944 m
1
 
 
IP cost (incremental): 
£202 m 
 
Total: £1,146 million 
        GRAND TOTAL = £1,150.3 million 
 
†  Calculated for 7 ELISAs: C. DIFF CHEK™-30, GA Clostridium difficile Antigen, Premier Toxin A+B, Remel ProSpecT, Ridascreen toxin A/B, Toxin A/B II, Vidas C. difficile 
Toxin A &B 
 
1
 Includes allowance for under-reporting of deaths. 
 
Detection & Identification of Infectious Agents (DIIA) Innovation Platform 
Area B: Hospital Acquired Infections (HAIs) 5 June 2009 24 
TABLE 4c:  Overview and summary of current testing for ESBL 
 
Clinical 
context 
for 
diagnosis 
Current UK test 
context 
Current tests used Current test capability Current economic impact 
Number of 
UK 
patients 
tested 
annually 
Settings 
where tests 
undertaken 
Type of 
tests used 
Test 
process 
Type of 
specimen 
Time to 
perform 
test/result 
Sensitivity/ 
Specificity 
Annual 
Testing Cost 
 
Annual  
Burden of disease  
ESBL 
clinical 
diagnosis 
N/A Laboratory Culture 
Culture 
followed by 
confirmatory 
tests 
Swab, 
Urine 
48h 
Mean‡: 
Sens 93% 
Spec 54% 
 
 
N/A 
Mortality: £74.7 - 
£149.4 m 
 
IP cost (incremental): 
~£247 m 
 
Total: £322 - £396 
million 
        GRAND TOTAL = > £322 million 
 
‡ Calculated for chromID ESBL, Chromagar CTX, Chromagar ECC, BLSE agar 
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TABLE 5a:  Predicted likely economic benefits of new tests for MRSA 
 
 
 
 
 
 
 
 
 
 
 
Main driver(s) for 
technology 
development 
 
New test 
UK role 
 
Target population/  
sub-population 
 Ideal new test requirement Predicted economics of new test  
 
 
 
 
Main driver for 
technology 
implementation 
 
Target 
population 
to be 
tested 
 
Number 
of UK 
patients 
 
Time 
to 
result 
 
Sens
/ 
Spec 
 
Setting 
for test 
 
 
Test  
process  
 
Break-
even 
Test 
Cost2 
 
 
Annual  
Cost 
saving 
 
Extra 
Cases4 
Detected 
per 
Annum 
 
MRSA Screening with 
selective agar slow 
and chromogenic 
media has a low 
sensitivity in less 
than 48 h. 
Molecular testing 
requires high 
volume and is 
expensive.   
Detection 
and 
screening 
Hospital 
 
 
 
 
 
 
 
 
Community
1
 
 
Screen: 
15.7 
million  
 
Diag: 
111,250 – 
500,000 
20 
mins 
95/95 Point of 
care 
Swab – 
nasal/rectal
/ 
wound 
“Dipstick” 
Single step 
 
 
N/A 
 
 
£1.8 -
£914 
million3 
 
 
5,118-
23,000 
Ability to detect 
MRSA at the 
bedside to 
eliminate the 
need for 
transporting of 
specimens5 and 
to enable medical 
staff to act on 
results 
immediately. 
 
1
 Modelling economic benefits for community infections would require separate exercise. 
2
  Break-even cost not available; will depend on assumed number of diagnostic tests (111,25- - 500,000), and infection transmission rate (range 0.3 to 0.7). 
3
 Based on reduced mortality costs and hospital costs associated with improved test performance (fewer false negatives/ false positives etc).  Figures are for varying 
   diagnostic test numbers, new test price and transmission rates (See Table 6a(i) for more detailed analysis) 
4
 MRSA infections only, excludes extra colonised patients detected. 
5
 Marginal cost saving through avoidance of in-hospital specimen transport to laboratory will be small; balanced against this, there may be extra bedside quality control 
   measures required.  
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TABLE 5b:  Predicted likely economic benefits of new tests for C. difficile 
 
 
 
 
 
 
 
 
 
 
 
Main driver(s) for 
technology 
development 
 
New test 
UK role 
 
Target population/  
sub-population 
 Ideal new test requirement Predicted economics of new test  
 
 
 
 
Main driver for 
technology 
implementation 
 
Target 
population 
to be 
tested 
 
Number 
of UK 
patients 
 
Time 
to 
result 
 
Sens
/ 
Spec 
 
Setting 
for test 
 
Test  
process  
 
Break-
even 
Test 
Cost2 
 
 
Annual  
Cost 
Saving3 
 
Extra 
Cases 
Detected 
per 
Annum 
 
C. 
difficile 
ELISA tests are the 
main test currently 
in use for the 
detection of toxin A 
and B but they lack 
specificity, 
sensitivity and have 
low PPV. All testing 
takes place within 
the laboratory and 
a stool sample is 
required  
Detection 
of disease  
Hospital 
 
 
 
 
 
 
 
 
 
 
Care 
Homes
1
 
 
427,000 20 
mins 
95/95 
 
Bedside  Blood 
Stool 
sample 
toxin 
detection 
Single 
step. 
Portable 
device 
 
 
£48.7 - 
£100.5 
[£79.9 - 
£172.8] 
 
 
£16.5-
£38.6 
million4 
 
[£29.8-
£69.5 
million] 5 
 
 
4,270-
7,686 
A bedside test 
will enable 
patients with 
diarrhoea to be 
isolated promptly 
and therefore 
limit the spread of 
the organism 
which has an 
ability to survive 
for extended 
periods within the 
environment. 
 
1
 Value of parameters required to model economic benefits for care home infections not available; would require separate data collection exercise. 
2
 Ratio of: (Current total spend on diagnosis + predicted savings due to improved test performance)/ Number of tests performed, 0.427 million) for Elisa vs Assay sens/spec 
   values Table 4b.   [Brackets: Same ratio based on Elisa vs Culture sens/spec values] 
3
 Based on reduced mortality costs and hospital costs associated with improved test performance (fewer false negatives/ false positives etc) 
4
 Based on current test characteristics (Elisa) vs Assay 
5
 Based on current test characteristics (Elisa) vs Culture 
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TABLE 5c:  Predicted likely economic benefits of new tests for ESBL 
 
 
 
 
 
 
 
 
 
 
 
Main driver(s) for 
technology 
development 
 
New test 
UK role 
 
Target population/  
sub-population 
 Ideal new test requirement 
Predicted economics of new 
test 1 
 
 
 
 
Main driver for 
technology 
implementation 
 
Target 
population 
to be 
tested 
 
Number 
of UK 
patients 
 
Time 
to 
result 
 
Sens
/ 
Spec 
 
Setting for 
test 
 
 
Test  
process  
 
Break-
even 
Test 
Cost 
 
 
Annual  
Cost 
Saving 
 
Extra 
Cases 
Detected 
 
ESBLs Currently screening 
tests are not 
specific as other 
mechanisms than 
ESBLs may cause 
positive screens. 
Currently different 
methods depending 
organism. 
Development of 
new enzymes. 
Current methods 
take greater than 
48h to result. 
Detection  Hospital 
 
 
Community 
 
 
 
N/A 
 
< 30 
mins 
95/>
95 
Laboratory 
 
 
 
 
 
 
 
 
 
 
 
Point of 
care  
 
“Dipstick” 
for urines  
 
Laboratory 
(single 
step) 
 
 
 
N/A 
 
 
N/A 
 
 
N/A 
Rising numbers 
of ESBLs 
(particularly in 
community UTIs) 
justify 
development of 
community rapid 
test2. 
1
 Value of parameters required to model economic benefits not available; would require separate data collection exercise. 
2
 Community infections excluded from Annual Burden of Disease estimates (see Table 4c). 
Detection & Identification of Infectious Agents (DIIA) Innovation Platform 
Area B: Hospital Acquired Infections (HAIs) 5 June 2009 28 
TABLE 6a:  Sensitivity analysis MRSA 
 
(i)  New Test Replaces Current Tests for Screening & Diagnosis 
 
Annual savings: New MRSA test used for screening all cases & diagnosis for max/ min number of patients tested 
No. UK patients 
with suspected 
MRSA 
(Diagnostic 
tests)
 1
 
Total Annual UK Cost (Screening
1
  + Diagnosis) 
 
Current tests
3
 New POC test
4
  
Culture 
screen 
PCR 
Screen 
New POC test (screen & diagnostic) 
Unit test cost = Culture cost 
New POC test (screen & diagnostic) 
Unit test cost = PCR cost 
111,250  £83.2 m £415.9 m - £1.8 to - £149.8 m
5
 + £182.9 to + £330.0 m
6
 
500,000  £86 m £418.7 m - £296 to - £914 m
5
 - £581.0 m
5
 to + £414.2 m
6
 
1
 Assumes all electives & emergencies are screened (~15.7 million patients)  
2
  Rows assume varying number suspected cases undergo diagnostic tests (111,250 – 500,000) 
3
  Assumes all patients are screened using same test: either using only culture or only PCR test. 
4
  Cost range in cell based on possible variation in infection transmission rate (0.3 to 0.7) 
5
  -£ = Saving compared to current tests 
6
  +£ = Increased cost compared to current tests 
 
 
(ii)  New Test Replaces Current Tests for Diagnosis 
 
Annual savings: New MRSA test (compared to current test) for different transmission rates & numbers tested 
Numbers Tested Transmission rate (false 
negatives & true positives
1
) 
Annual Savings 
(compared to current test) 
Extra cases detected 
(per annum) 
111,250 0.3 - £  85.0 m 5,118 
0.5  - £ 159.0 m 
0.7  - £ 233.0 m 
500,000 0.3  - £ 382.0 m 23,000 
0.5  - £ 714.0 m 
0.7  - £1,000.0 m 
1
 True positives (MRSA infection) take 48 hr to be detected using culture methods; during this time they are assumed to transmit infection at this rate. 
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(iii)  MRSA Screening: Types of Results, Decolonisation Costs and Extra Colonisations for Different Screening Tests (15.7 million) 
 
 Type of test used for screening on admission 
 
Annual Results Culture 
 
PCR 
 
New PoC 
 
No. True Positives 791,280 1,000,090 1,044,050 
No. False Positives 438,030 585,040 730,050 
No. False Negatives 307,720 98,910 54,950 
Annual Cost 
 
   
Decolonisation Cost £9.3 million £12.0 million £13.5 million 
Extra colonisations 
 
   
Time to result 48 hrs 2 hrs 20 mins 
Transmission 0.3 0 0 
Extra patients colonised 329,700 0 0 
 
 
 
TABLE 6b:  Sensitivity analysis C. difficile (New Test Replaces Current Test for Diagnosis) 
 
Annual savings: New C. difficile test (compared to current test) for different transmission rates 
Numbers Tested Transmission rate 
per false negative 
Elisa vs. Culture Extra cases detected 
(per annum) 
Elisa vs. Assay Extra cases detected 
(per annum) 
427,000 0.3 + £ 3.2 m
1
 7,686 + £ 1.8 m 4,270 
0.5 - £16.6 m
2
 - £ 9.2 m 
0.7 - £36.4 m - £20.2 m 
1
 +£ = Increased cost compared to current test 
2
  -£ = Saving compared to current test 
Detection & Identification of Infectious Agents (DIIA) Innovation Platform 
Area B: Hospital Acquired Infections (HAIs) 5 June 2009 30 
 
Figure 1a: New MRSA test used for diagnosis (compared to current test) 
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Figure 1b: New C. difficile test used for diagnosis (compared to current test) 
 
Savings due to PoC test: Cdiff
-10
-5
0
5
10
15
20
25
30
35
40
0.3 0.5 0.7
Infectivity Rate
£
 m
il
li
o
n
s
ELISA vs Assay ELISA vs Culture
 
 
 
 
Detection & Identification of Infectious Agents (DIIA) Innovation Platform 
Area B: Hospital Acquired Infections (HAIs) 5 June 2009 32 
 
Annex 1a:  MRSA Treatment and Diagnosis Cost Estimates: Input parameters and assumptions 
 
TREATMENT Source Unit cost/number Total annual cost (UK) Comment 
Inpatient episodes   £106.75 million  
  22,250 MRSA infections per year in 
England @ £4,798 per case.  
 
 
 
Decolonisation treatment   £6.9 million  
  £7.60 per patient.  
11 million elective patients screened. 
7% true positive rate. Allowing for false 
+ves = 907,100@£7.60 
  
TOTAL TREATMENT  Inpatient costs + decolonisation £113.65 million  
 
DIAGNOSIS Source Unit cost/number Total annual cost (UK) Comment 
Agar   £623,890  
  £7.80 (positive), £5.06 (negative) 
1 sample per patient, 20% positive: 
Average cost: (0.2×£7.80)+(0.8×£5.06) 
111,250 patients tested (based on 22,250 
MRSA infections) 
 
 
£5.61 per patient 
 
£623,890 
 
Broth enrichment   £846,390  
  £10.16 (positive), £6.97 (negative) 
1 sample per patient, 20% positive: 
Average cost: (0.2×£10.16)+(0.8×£6.97) 
111,250 patients tested (based on 22,250 
MRSA infections) 
 
 
£7.61 per patient 
 
£846,390 
 
TOTAL DIAGNOSIS   £623,890 - £846,390  
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CURRENT SCREENING     
Screening tests   £68.34 million  
  Elective agar: 10.5 million patients 
Positive: 735,000@£7.80 
Negative: 9,765,000@£5.06 
Elective PCR: 0.5 million patients 
Positive: 35,000@£26.4 
Negative: 465,000@£26.4 
 
 
£5.73million 
£49.41 million 
 
£0.92 million 
£12.28 million 
 
 
GRAND TOTAL 
(CURRENT) 
 Inpatient costs + decolonisation + diagnostic 
testing + screening electives 
£69 million  
 
 
FUTURE SCREENING*     
All screening tests (by 2011)   £181.88 million  
  Rapid PCR: £26.46 per test 
4.7 million emergency patients@£26.46 
11 million elective patients: 
Positive: 770,000@£7.80 
Negative: 10,230,000@£5.06 
 
£124.08 million 
 
£6 million 
£51.8 million 
 
Extra decolonisations   £2.50 million  
  7% of 4.7 million emergency patients 
329,000@£7.60 
  
TOTAL ADDITIONAL 
SCREENING (2011)  
  £126.58 million  
  4.7 million extra screened @ £26.46 
329,000 extra decolonised @ £7.60 
£124.08 million 
£2.50 million 
 
* Excludes diagnostic test costs 
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Annex 1b:  C. difficile Treatment and Diagnosis Cost Estimates: Input parameters and assumptions 
 
TREATMENT Source Unit cost/number Total annual cost (UK) Comment 
Inpatient care   £202.0 million  
  Additional cost: £4,300 per CDI case 
Assume 80% cases lead to no re-admission 
80%*42,700 hospital acquired cases 
 
£146.9 million 
 
Re-admissions (extra)   £55.1 million  
  Assume 20% CDI cases lead to re-admission 
Average cost per CDI case raised to: £6,450 
Total inpatient: 20%*42,700@£6,450 
 
 
 
£55.1 million 
 
 
DIAGNOSIS Source Unit cost/number Total annual cost (UK) Comment 
Current testing   £4.3 million  
  427,000 @ £10  
£4.3 million 
 
 
GRAND TOTAL   Inpatient costs + readmissions + diagnostic 
tests 
£206.3 million  
 
Detection & Identification of Infectious Agents (DIIA) Innovation Platform 
Area B: Hospital Acquired Infections (HAIs) 5 June 2009 35 
 
Annex 1c:  ESBL Treatment and Diagnosis Cost Estimates: Input parameters and assumptions 
 
TREATMENT Source Unit cost/number Total annual cost (UK) Comment 
Inpatient care   ~£247 million  
  Additional cost: £8,225 per ESBL case 
Assume 30,000 cases 
 
~£246.75 million 
 
 
DIAGNOSIS Source Unit cost/number Total annual cost (UK) Comment 
Current testing   N/A  
  N/A  
N/A 
 
 
GRAND TOTAL   Inpatient costs + screening/diagnostic tests > £247 million  
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